• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Cancer >Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases
【24h】

Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases

机译：肾上腺转移凝聚的低剂量立体定向体放射治疗（SBRT）的单制度化结果分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adrenal gland metastases are a common diagnostic finding in various tumor diseases. Due to the increased use of imaging methods, they are diagnosed more frequently, especially in asymptomatic patients. SBRT has emerged as a new, alternative treatment option in the field of radiation oncology. In the past, it was often used for treating inoperable lung, liver, prostate, and brain tumors. Meanwhile, it is also an established keystone in the treatment of oligometastatic diseases. This retrospective study aims to evaluate the effect of low-dose SBRT in patients with adrenal metastases. We analyzed a group of 31 patients with 34 adrenal gland lesions treated with low-dose SBRT between July 2006 and July 2019. Treatment-planning was performed through contrast-enhanced CT, followed by image-guided stereotactic radiotherapy using cone-beam CT. The applied cumulative median dose was 35?Gy; the median single dose was 7?Gy. We focused on local control (LC), progression-free survival (PFS), overall survival (OS), as well as acute and late toxicity. Seven adrenal gland metastases (20.6%) experienced local failure, 80.6% of the patients faced a distant progression. Fourteen patients were still alive. Median follow-up for all patients was 9.8?months and for patients alive 14.4?months. No treatment-related side-effects grade 2 occurred. Of all, 48.4% suffered from acute gastrointestinal disorders; 32.3% reported acute fatigue, throbbing pain in the renal area, and mild adrenal insufficiency. Altogether, 19.4% of the patients faced late-toxicities, which were as follows: Grade 1: 12.9% gastrointestinal disorders, 3.2% fatigue, Grade 2: 9.7% fatigue, 6.5% headache, 3.2% loss of weight. The 1-year OS and probability of LF were 64 and 25.9%, respectively. Low-dose SBRT has proven as an effective and safe method with promising outcomes for treating adrenal metastases. There appeared no high-grade toxicities grade 2, and 79.4% of treated metastases were progression-free. Thus, SBRT should be considered as a therapy option for adrenal metastases as an individual therapeutic concept in the interdisciplinary discussion as an alternative to surgical or systemic treatment.
机译：肾上腺转移酶是各种肿瘤疾病中的常见诊断发现。由于成像方法的使用增加，它们更频繁地诊断出来，特别是在无症状患者中。 SBRT在辐射肿瘤学领域中出现了一种新的替代治疗选择。过去，它通常用于治疗无法操作的肺，肝，前列腺和脑肿瘤。同时，它也是治疗寡粒子疾病的建立的梯度。该回顾性研究旨在评估低剂量SBRT在肾上腺转移患者中的作用。我们分析了31例31例患有34例肾上腺病变的31例肾上腺病灶，在2006年7月至2019年7月期间治疗。通过对比增强CT进行治疗计划，然后使用锥形束CT进行图像引导的立体定向放疗。所施加的累积中值剂量为35？GY;中位单剂量为7？GY。我们专注于局部对照（LC），无进展生存（PFS），整体存活（OS），以及急性和晚期毒性。七个肾上腺转移（20.6％）经历了局部失败，80.6％的患者面临着遥远的进展。十四名患者还活着。所有患者的中位后续随访9.8个月，患者活着14.4个月。没有治疗相关的副作用> 2级发生。总共48.4％患有急性胃肠道疾病; 32.3％报告急性疲劳，肾脏面积疼痛，肾上腺肾脏不足。共有19.4％的患者面临晚期毒性，如下：1级：12.9％胃肠疾病，3.2％疲劳，2级疲劳，头痛6.5％，重量损失3.2％。 1年的OS和LF的概率分别为64和25.9％。低剂量SBRT已被证明是一种有效和安全的方法，具有治疗肾上腺转移的有希望的结果。没有高档毒性> 2级，79.4％的治疗转移是无进展的。因此，SBRT应被视为肾上腺转移作为跨学科讨论中的个体治疗概念的治疗选择，作为手术或全身治疗的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号